Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon

Trial Profile

Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
  • Indications Cardiovascular disorders; Pregnancy; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 08 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top